Haemolysis during Sample Preparation Alters microRNA Content of Plasma

Michaela B. Kirschner3, Steven C. Kao1,2, J. James Edelman3, Nicola J. Armstrong4, Michael P. Valley3, Nico van Zandwijk1, Glen Reid1*

1 Asbestos Diseases Research Institute (ADRI), Bernie Banton Centre, University of Sydney, Sydney, Australia, 2 Department of Medical Oncology, Concord Hospital, Concord, Australia, 3 Cardiothoracic Surgical Unit, Royal Prince Alfred Hospital, The Baird Institute, Faculty of Medicine, University of Sydney, Sydney, Australia, 4 Cancer Research Program, Garvan Institute for Medical Research and School of Mathematics and Statistics, University of New South Wales (UNSW), Sydney, Australia

Abstract

The presence of cell-free microRNAs (miRNAs) has been detected in a range of body fluids. The miRNA content of plasma/serum in particular has been proposed as a potential source of novel biomarkers for a number of diseases. Nevertheless, the quantification of miRNAs from plasma or serum is made difficult due to inefficient isolation and lack of consensus regarding the optimal reference miRNA. The effect of haemolysis on the quantification and normalisation of miRNAs in plasma has not been investigated in detail. We found that levels of miR-16, a commonly used reference gene, showed little variation when measured in plasma samples from healthy volunteers or patients with malignant mesothelioma or coronary artery disease. Including samples with evidence of haemolysis led to variation in miR-16 levels and consequently decreased its ability to serve as a reference. The levels of miR-16 and miR-451, both present in significant levels in red blood cells, were proportional to the degree of haemolysis. Measurements of the level of these miRNAs in whole blood, plasma, red blood cells and peripheral blood mononuclear cells revealed that the miRNA content of red blood cells represents the major source of variation in miR-16 and miR-451 levels measured in plasma. Adding lysed red blood cells to non-haemolysed plasma allowed a cut-off level of free haemoglobin to be determined, below which miR-16 and miR-451 levels displayed little variation between individuals. In conclusion, increases in plasma miR-16 and miR-451 are caused by haemolysis. In the absence of haemolysis the levels of both miR-16 and miR-451 are sufficiently constant to serve as normalisers.

Introduction

MicroRNAs (miRNAs), a class of 18–25 nt long non-coding RNAs, are post-transcriptional modulators of gene expression [1–3]. They are involved in the regulation of normal physiological processes and there is rapidly increasing evidence that they also play a prominent role in cancer [2,4,5] and non-malignant conditions such as heart disease [6]. Recently a number of studies have shown that miRNAs are readily detectable in body fluids, and the presence of specific miRNA patterns in plasma of diseased (cancer) patients has raised the possibility of their use as biomarkers [7–9]. MiRNAs in plasma/serum seem to be more stable than mRNA and this has been attributed to their encapsulation into microvesicles [10,11]. More recently, association of extracellular miRNAs with nucleophosmin [12], argonaute 2 [13,14] and high density lipoproteins [15] has been demonstrated, suggesting alternative mechanisms of miRNA export and transport in the circulatory system.

Since the first reports revealing the presence of miRNAs in plasma and serum, numerous studies have identified distinct miRNA expression patterns associated with disease and have proposed them as candidate biomarkers [9]. However, when comparing the methods applied in different studies, a consensus on the best methods for the measurement and accurate quantification of disease-related miRNA patterns in body fluids has yet to be reached.

When developing miRNAs as biomarkers one of the first issues to consider is that each body fluid appears to have a normal spectrum of miRNAs [8], presumably a reflection of normal physiology. MiRNAs in plasma and serum are thought to contribute to the (normal) functioning of the circulatory and the immune system [16,17]. Moreover, different blood cell components seem to be characterised by a distinct miRNA profile. While red blood cells (RBCs) contain high levels of miR-451 and miR-16, these miRNAs, which are thought to play a role in erythropoiesis [16,18], were found at low levels in leucocytes and platelets [19,20]. MiRNAs in blood may also be present in cell-derived microvesicles, exosomes and apoptotic bodies, which seem to shuttle specific subsets of miRNAs to recipient cells [21–23].

The measurement and exact quantification of miRNA are further hampered by the low yields of RNA in serum or plasma, complicating normalisation strategies that are based on quantification of total RNA. One of the most frequently used strategies to overcome this problem when quantifying miRNAs is the use of a
miR-16 levels in plasma obtained at three separate occasions from varied by only 2 cycles (Figure 1A). Furthermore, measurements of those of miR-451 showed less variation and those of miR-16

miR-15b and -24 varied between healthy and diseased individuals, with non-haemolysed samples.

in whole blood

RBCs represent the major source of miR-16 and miR-451

Presence of haemolysis in plasma samples affects levels of miR-16 and miR-451

A number of groups have proposed the use of a stably expressed miRNA such as miR-16 or the small nucleolar RNA RNU6B as a normaliser [24–27], but others have reported significant variation in the levels of these normalisers [28,29]. This has led to the adoption of normalisation strategies based on the detection/ quantification of ‘spiked in’ synthetic miRNAs [30–32]. Since miR-16 is one of the most abundant miRNAs present in RBCs [20], we theorised that haemolysis may be responsible for increasing levels of this candidate reference gene.

In this study we assessed the variation of miR-16 levels in plasma samples from healthy individuals, patients with malignant mesothelioma (MM) and coronary artery disease (CAD). We found comparable miR-16 levels in the different groups of samples, but only in the absence of haemolysis. Only in plasma samples with a haemoglobin content equivalent to an absorbance of less than 0.2 at 414 nm were the levels of miR-16 similar enough to be suitable for normalisation.

Results

Plasma miR-16 levels show little variation between individuals with different physiological conditions

Investigating the variation of a number of potential reference genes we found that while four moderately abundant miRNAs, hsa-miR-16, -15b, -24 and -451 were readily detectable in plasma samples the small nucleolar RNA RNU6B could not be detected in any sample (data not shown). Levels of the four miRNAs were compared in the plasma (without obvious signs of haemolysis) of nine healthy volunteers, eighteen patients with MM and ten patients with CAD. While the Cq (quantification cycle) values for miR-15b and -24 varied between healthy and diseased individuals, those of miR-451 showed less variation and those of miR-16 varied by only 2 cycles (Figure 1A). Furthermore, measurements of miR-16 levels in plasma obtained at three separate occasions from the same individual varied by less than 1 cycle (Figure 1B).

RBCs represent the major source of miR-16 and miR-451 in whole blood

Measurement of both miR-451 and miR-16 levels in whole blood as well as RBCs, peripheral blood mononuclear cells (PBMCs) and plasma separated by Ficoll-Paque revealed that RBCs represent the most likely source of variation in levels of these miRNAs in plasma/serum. The number of copies of both miR-451 and miR-16 in (whole) blood mainly derived from RBCs, while PBMCs and plasma were found to contribute less than 1% of copies of both miRNAs (Table 1).
whereas miR-24 levels were unchanged in the presence of haemolysis (Figure S1A). Measurement of three more miRNAs present at moderate levels in plasma showed that while miR-92a levels also increased with the degree of haemolysis those of miR-155 and miR-625* remained stable (Figure S1B).

Analysing our series of haemolysed and non-haemolysed plasma samples (9 healthy, 20 MM and 16 CAD), we further assessed the levels of all four miRNAs. We found that using an absorbance at 414 nm of higher than 0.2 as cut-off to distinguish haemolysed and non-haemolysed plasma (Figure 4A, \( p < 0.001 \)) significantly decreased the variability in both miR-451 (Figure 4B, \( p = 0.008 \)) and miR-16 (Figure 4C, \( p = 0.026 \)) levels. Exclusion of haemolysed plasma did not reduce the variability in miR-15b (Figure 4D, \( p = 0.893 \)) and miR-24 (Figure 4E, \( p = 0.086 \)) levels.

Effect of haemolysis on potential miRNA biomarkers for CAD

To investigate the effect of haemolysis on miRNAs proposed as biomarkers, we measured levels of miR-92a and miR-155, two miRNAs previously shown to be present at lower levels in the plasma of CAD patients than in healthy controls. The levels of miR-92a were also elevated in haemolysed plasma of two MM, 1 CAD patient and 1 healthy control compared with matched non-haemolysed samples from the same individuals. In contrast to miR-16 and miR-451, however, the increase in miR-92a calculated by using the \( 2^{-\Delta\Delta Ct} \) [34] method did not seem to correlate with the degree of haemolysis (Figure 5A). In contrast to miR-92a, the levels of miR-155 were only increased in two out of four haemolysed samples (Figure 5A). Quantification of miRNA
using the $2^{-\Delta\Delta Cq}$ method with normalisation to miR-16 resulted in lower miRNA levels in haemolysed than in non-haemolysed samples (Figure 5B), although the measurement in the dilution series (Figure S1B) showed a correlation between the degree of haemolysis and miR-92a levels. Similar results were also obtained for measurement of miR-15b and miR-24 in the same samples (data not shown).

**Discussion**

A number of recent studies have shown that miRNAs are detectable in a variety of body fluids and miRNAs in plasma and serum have attracted particular attention as candidate biomarkers for a range of diseases [9]. However, although miRNAs are readily detectable in both plasma and serum, the identification of disease-specific miRNAs or miRNA expression patterns is complicated by the fact that the majority of miRNAs in blood do not seem to be affected by the presence of disease. Studies profiling the miRNA content of normal serum have for example shown that there is extensive overlap between the miRNA profiles of serum and blood cells, suggesting a physiological role for these miRNAs [28,35]. Detailed studies have provided evidence that miR-451 and miR-16 are involved in the late stages of erythropoiesis, and that miR-451 is erythroid specific [18,20]. In contrast, miR-155 was found at higher levels in platelets and B/T lymphocytes, and miR-223 was found in high levels in granulocytes and monocytes, suggesting that they play a role in the differentiation of these cell types [16,20,36].

In addition to miRNAs present in different blood cell types, the contents of microvesicles represent another source for both normal and disease-specific miRNAs found in the circulation. Microvesicles (MVs) are released by normal cells including haematopoietic lineages [22,23,35], and are thought to act as a shuttle to deliver nucleic acids, including miRNAs, to recipient cells [22,23]. Furthermore it was shown that MVs released by tumour cells contain cancer-specific miRNA signatures that differentiate them from MVs released by normal cells [37,38]. Comparisons between cellular and exosomal miRNA content also showed that several miRNAs can be found in higher concentrations in exosomes than in the corresponding tumour cell, suggesting selective packaging of miRNAs into exosomes [22].

![Figure 3. Relationship between free haemoglobin and miRNA content of plasma samples.](image-url)
The quantification of miRNAs in blood is complicated by the high protein content and low RNA concentrations of plasma/serum. Even with the use of carrier molecules to improve isolation [39,40], yields are often at or below the threshold for accurate quantification by spectrophotometric analyses [41]. The low yields of RNA extracted from plasma make a quantification of miRNAs in copies per nanogram total RNA difficult. These problems are not unique to plasma or serum. A recent study evaluating the use of different reference RNAs for a range of tissue samples has shown that normalisation to total RNA input is highly unstable [42]. An additional argument against the use of total RNA as a normaliser is the observation that the total plasma/serum RNA content may change (increase) with disease state [43].

A frequently used alternative approach for normalisation is the use of a ubiquitously expressed RNA or miRNA as reference gene. While the small nucleolar RNA RNU6B is often used for normalisation when quantifying miRNAs from tissue samples [44,45], levels of this small RNA were found to be variable in a significant number of studies [25,26,28,35,46]. A range of miRNA candidates for normalisation has also been evaluated, with miR-16 the most frequently used. However, while some studies showed that miR-16 was present at similar levels in samples from healthy individuals and diseased patients [25–27,47], other studies suggested that miR-16 levels were not consistent enough to be used for normalisation [28,29]. We have shown that the plasma levels of miR-16 from healthy controls as well as patients with either MM or CAD were very similar (Figure 1A). The low coefficient of variance of miR-16 in individuals with and without disease, together with the observation that the levels of miR-16 in plasma taken at separate occasions from the same individual varied by less than one Cq in RT-qPCR (Figure 1B) strengthen our conclusion that miR-16 levels can serve as a reference for normalisation.

Figure 4. Determination of a cut-off level of free haemoglobin to distinguish haemolysed from non-haemolysed plasma. Levels of free haemoglobin, miR-451, -16, -15b and -24 were measured in a cohort of non-haemolysed (circles, n = 23) and haemolysed (squares, n = 22) plasma samples from healthy volunteers and MM or CAD patients. Applying a cut-off at an absorbance at 414 nm of higher than 0.2 (A) to remove haemolysed samples from the analysis significantly decreased the variability for both miR-451 (B) and miR-16 (C), and showed that in non-haemolysed samples miR-16 and miR-451 levels showed little variation in samples from individuals with different physiological conditions. In contrast the variability of miR-15b (D) and miR-24 (E) levels was not reduced by exclusion of haemolysed samples. * p<0.05.

doi:10.1371/journal.pone.0024145.g004

The quantification of miRNAs in blood is complicated by the high protein content and low RNA concentrations of plasma/serum. Even with the use of carrier molecules to improve isolation [39,40], yields are often at or below the threshold for accurate quantification by spectrophotometric analyses [41]. The low yields of RNA extracted from plasma make a quantification of miRNAs in copies per nanogram total RNA difficult. These problems are not unique to plasma or serum. A recent study evaluating the use of different reference RNAs for a range of tissue samples has shown that normalisation to total RNA input is highly unstable [42]. An additional argument against the use of total RNA as a normaliser is the observation that the total plasma/serum RNA content may change (increase) with disease state [43].

A frequently used alternative approach for normalisation is the use of a ubiquitously expressed RNA or miRNA as reference gene. While the small nucleolar RNA RNU6B is often used for normalisation when quantifying miRNAs from tissue samples [44,45], levels of this small RNA were found to be variable in a significant number of studies [25,26,28,35,46]. A range of miRNA candidates for normalisation has also been evaluated, with miR-16 the most frequently used. However, while some studies showed that miR-16 was present at similar levels in samples from healthy individuals and diseased patients [25–27,47], other studies suggested that miR-16 levels were not consistent enough to be used for normalisation [28,29]. We have shown that the plasma levels of miR-16 from healthy controls as well as patients with either MM or CAD were very similar (Figure 1A). The low coefficient of variance of miR-16 in individuals with and without disease, together with the observation that the levels of miR-16 in plasma taken at separate occasions from the same individual varied by less than one Cq in RT-qPCR (Figure 1B) strengthen our conclusion that miR-16 levels can serve as a reference for normalisation.
Quantification of miR-451 and miR-16 levels in blood and its different components showed that the level of both miRNAs in whole blood are dominated by the miRNA content of red blood cells and that only a fraction is derived from plasma or PBMCs (<1%). Thus the increase in miR-16 levels is likely to be caused by rupture of RBCs. In vitro haemolysis is a relatively common phenomenon during collection of blood. Occasionally, when multiple tubes from the same sampling were separated, both haemolysed and non-haemolysed plasma were obtained. Using non-haemolysed and haemolysed plasma isolated from the same collection we were able to show that levels of both miR-451 and miR-16 in plasma increased with the degree of haemolysis (Figure 2). These data are in line with a recent study showing that the levels of certain miRNAs, such as miR-16 can vary with haemolysis [48].

Using a dilution series of RBCs in plasma, we confirmed that the levels of both miRNAs were already significantly increased before a change in plasma colour from yellow to pink was visible (Figure 3), while other miRs such as miR-24 and miR-155 remained unchanged (Figure S1). Applying these data to a series of control and patient samples with different degrees of haemolysis we found that using a cut-off level based on measurement of free haemoglobin allowed us to distinguish between non-haemolysed and haemolysed plasma. Removing haemolysed samples resulted in significantly decreased variance in levels of both miR-451 and miR-16 (Figure 4).

A number of studies have investigated the potential use of miRNAs, including miRs-92a and -155, as plasma biomarkers of heart disease [24,31,49–51]. MiR-92a is a member of the miR-17–92 cluster of regulators of angiogenesis with expression predominantly in endothelial cells [52,53], whereas miR-155 was found to be highly expressed in platelets as well as being involved in maturation of B and T cells [16,20,36]. Comparing levels of miR-92a and miR-155 in non-haemolysed and haemolysed plasma collected from patients revealed that, like miR-16 and miR-451, the absolute levels of miR-92a are increased in haemolysed plasma. In contrast only half of the haemolysed samples showed an increase in miR-155. Most importantly, however, the magnitude of increases in miR-92a and miR-155, as

![Figure 5. Levels of potential biomarkers for CAD in haemolysed and non-haemolysed plasma.](image-url)
samples were then mixed vigorously using a vortex to increase cell 2 after centrifugation at manufacturer’s protocol and processed further immediately.

further processing. PBMCs were separated from whole blood room temperature. Plasma and RBCs were stored at collection, the tubes were centrifuged for 20 min at 2500 g at occasions, while blood from patients with either MM or CAD from healthy volunteers were collected on three separate.

miRNA analysis using a normalisation strategy based on an measurement of free haemoglobin in plasma samples might be a of plasma samples is a frequently occurring event which increases the plasma levels of RBC-derived miRNAs. It also has the potential to influence the measurement of any candidate miRNA biomarker(s) that is also present in RBCs. This suggests that the measurement of free haemoglobin in plasma samples might be a simple test method to determine whether a sample is suitable for miRNA analysis using a normalisation strategy based on an endogenous miRNA.

Materials and Methods

Ethics Statement

This study was conducted according to the principles expressed in the Declaration of Helsinki and was specifically approved by the Sydney Local Health Network, Human Research Ethics Committees based at Concord Repatriation General Hospital and Royal Prince Alfred Hospital. All samples were collected from individuals who had given written informed consent for this study.

Blood collection

Peripheral blood samples were collected from the antecubital fossa into one to three 4 ml or 10 ml Vacutainer Plus K3EDTA tubes (BD Biosciences) using a butterfly device (21G). Samples from healthy volunteers were collected on three separate occasions, while blood from patients with either MM or CAD was collected prior to treatment. Within 30 min of blood collection, the tubes were centrifuged for 20 min at 2500 g at room temperature. Plasma and RBCs were stored at −80°C until further processing. PBMCs were separated from whole blood using Ficoll-Paque PLUS (GE Healthcare) according to the manufacturer’s protocol and processed further immediately. RBC lysate was prepared by immediately freezing the RBC pellet after centrifugation at −80°C. Prior to use the thawed RBC samples were then mixed vigorously using a vortex to increase cell lysis.

Synthetic RNAs

Synthetic RNAs corresponding in sequence to the mature sequences of hsa-miR-16, hsa-miR-451, hsa-miR-15b and hsa-miR-24 were synthesised by Integrated DNA Technologies.

RNA isolation

Total RNA was isolated using the mirVana PARIS miRNA isolation kit (Ambion/Applied Biosystems) according to the manufacturer’s instructions for isolation of total RNA, with the addition of a second phenol-chloroform extraction of the aqueous phase obtained after the first extraction to aid in removal of the high protein content. Following the denaturing step, 100 µg of mussel glycogen (Roche) was added as carrier to aid RNA isolation. Isolated RNA eluted in 100 µl H2O was quantified using a Nanophotometer (Implen) with readings at 260 and 280 nm. RNA samples were stored at −80°C until further processing.

Real-time RT-qPCR

Quantification of miRNA content in RNA from plasma was performed using stem-loop primers for reverse transcription and TaqMan primers/probe specific for each miRNA (Applied Biosystems, see Table S2 for TaqMan Assay IDs). For reverse transcription we used the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) with the following reaction conditions: 30 min at 16°C, followed by 30 min at 42°C and 5 min at 85°C. For each plasma sample the reaction was carried out in a total reaction volume of 5 µl with a fixed volume of 1.67 µl isolated RNA as template.

For absolute quantification of miRNAs we generated standard curves using synthetic RNAs (Integrated DNA Technologies) corresponding to the mature miRNAs detected. A dilution series of these synthetic RNAs ranging from 105 to 10-1 miRNA copies per qPCR reaction was generated in the presence of 1 ng/µl yeast tRNA (Roche). The reverse transcriptions for the standard curves were performed in a total reaction volume of 10 µl with 2.96 µl of a synthetic miRNA solution of appropriate concentration using the same reaction conditions as for the plasma samples. All cDNA was used immediately in qPCR reactions or stored at −20°C for use within one week.

Following reverse transcription, as recommended by the manufacturer, the cDNA was further diluted by addition of 28.9 µl H2O in order to achieve a final dilution of 1:13 of the RT product. 2.25 µl of the diluted RT product were then used as template in a triplicate qPCR with a total reaction volume of 10 µl. Amplification was performed using miRNA TaqMan primers/probe specific for each miRNA together with TaqMan 2x Universal PCR MasterMix, No AmpErase UNG (Applied Biosystems) with enzyme activation for 10 min at 95°C followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. For generation of standard curves, the RT product was diluted 1:10 in H2O and 2.25 µl of this dilution were used as template. No template and no RT samples were included as negative controls. The qPCR reactions were set up manually and run on a Stratagene Mx3000P instrument. Cq (quantification cycle) values were determined using adaptive-baseline and background-based threshold (cycle-range 5–8) using the MxPro Mx3000P v4.10 software (Stratagene).

Relative levels of miRNAs in haemolysed and non-haemolysed plasma (Figure 5) were calculated using either the 2−ΔΔCq or the 2−ΔCq method [34]. Briefly, in case of 2−ΔΔCq (Figure 5A) ΔCq was calculated for each miR by subtracting the Cq of the non-haemolysed samples from its matching haemolysed value. For 2−ΔCq calculations for each sample the first ΔCq was calculated by subtracting the miR-16 value from the Cq of the miR of interest. The ΔCq of the non-haemolysed sample was then subtracted from that of its matching haemolysed sample.

Haemoglobin measurement

Levels of free haemoglobin in the plasma samples were measured by spectral analysis [33]. Absorbance peaks at 414, 541 and 576 nm were indicative of free haemoglobin, with higher absorbance in samples with higher degree of haemolysis.
Differences in variability of expression levels were analysed using Levene's test for equality of variances. P-values are unadjusted and a value of ≤0.05 was considered significant. Analyses were conducted using PASW statistics 18 software.

Supporting Information

Figure S1  Relationship between free haemoglobin and miRNA content of plasma samples. (A) Levels of miR-15b and miR-24 in plasma samples from the RBC dilution series were quantified using a standard curve. While levels of miR-15b increased with the degree of haemolysis, those of miR-24 remained similar in all samples. (B) Changes in raw Cq values of miR-92a, miR-155 and miR-625* in samples from the same dilution series. Only miR-92a levels changed with increased haemolysis.

Table S1 Measurement of additional potential markers of haemolysis in the RBCs in plasma dilution series. Levels of LDH, ALT and AST and the concentration of haemoglobin in mg/dL in the samples of the dilution series were measured in the Diagnostic Pathology Unit, Concord Repatriation General Hospital, Sydney, using the Roche Modular System.

Acknowledgments

We thank Peter Forrest and Dorothy Kouziou from the Diagnostic Pathology Unit of Concord Repatriation General Hospital in Sydney for analysing additional markers of haemolysis. We further thank our colleagues for helpful discussions and critical evaluation of the manuscript.

Author Contributions

Conceived and designed the experiments: MBK GR. Performed the experiments: MBK. Analyzed the data: MBK NJA GR. Contributed reagents/materials/analysis tools: SCK JEE MPV. Wrote the paper: MBK NvZ GR.

References

1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
2. Lee VS, Danza A (2009) MicroRNAs in cancer. Annu Rev Pathol 4: 199–227.
3. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.
4. Gazzano R, Calin GA, Croce CM (2009) MicroRNAs in Cancer. Annu Rev Med 60: 167–179.
5. Ma J, Dong C, J C (2010) MicroRNA and drug resistance. Cancer Gene Ther 17: 529–331.
6. Small EM, Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469: 336–342.
7. Hanson EK, Lubenow H, Ballantyne J (2009) Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal Biochem 387: 303–314.
8. Weber JA, Baxter DH, Zhang S, Huang DY, How Huang K, et al. (2010) The MicroRNA Spectrum in 12 Body Fluids. Clin Chem 56: 1733–1741.
9. Reid G, Kirschner MB, van Sandwijk N (2010) Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol doi:10.1016/j.critrevonc.2010.11.004.
10. Cortez MA, Calin GA (2009) MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 9: 703–711.
11. Kosaka N, Isguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087–2092.
12. Wang K, Zhang S, Weber J, Baxter D, Galas DJ (2010) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic acids research 38: 7240–7259.
13. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic acids research.
14. Arroyo JD, Chevillet JR, Kroh EM, Rul JK, Pritchard CC, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108: 5003–5008.
15. Vickers KC, Palminsao BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature cell biology 13: 423–433.
16. Vasilyut D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J (2010) The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84: 1–16.
17. Zhou B, Wang S, Mayo C, Bartel DP, Lodish HF (2007) miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 104: 7080–7085.
18. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT (2007) Regulated expression of microRNAs in normal and polycytemia vera erythropoiesis. Exp Hematol 35: 1657–1667.
19. Ramkisson SH, Mainwaring LA, Ogawasawa Y, Keyvanfar K, McCoy JP, Jr., et al. (2006) Hematopoietic-specific microRNA expression in human cells. Leuk Res 30: 643–647.
20. Merkerova M, Belieкова M, Bruchova H (2008) Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 81: 304–310.
21. Cimino-Friedman MG, Bruno S, Strepone L, Aghemo G, et al. (2010) Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 5: e11803.
22. Valadi H, Ekstrom K, Bossio A, Sjostrand M, Lee JI, et al. (2004) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654–659.
23. Wang K, Zhang S, Weber J, Baxter D, Galas DJ (2010) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res.
24. Ai T, Zhang R, Li Y, Pu J, Lu Y, et al. (2010) Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 391: 73–77.
25. Huang Z, Huang D, Ni S, Peng Z, Sheng W, et al. (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 119–126.
26. Lawrie CH, Gal S, Dunlop HM, Puskarzan B, Liggins AP, et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672–677.
27. Henehan HM, Müller N, Lowery AJ, Sweeney KJ, Newell J, et al. (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251: 499–505.
28. Chen B, Ya B, Ya I, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997–1006.
29. Ng EK, Chong WW, Jn H, Lam EK, Shin YY, et al. (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 59: 1375–1381.
30. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10313–10318.
31. Wang GK, Zhu JG, Zhang JT, Li Q, Li Y, et al. (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659–666.
32. Wang JF, Yu ML, Yu G, Bian J, Deng XM, et al. (2010) Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 387: 104–108.
33. Wong CH, Song C, Heng KS, Kee IH, Tien SL, et al. (2006) Plasma free hemoglobin: a novel diagnostic test for assessment of the depth of burn injury. Plast Reconstr Surg 117: 1206–1213.
34. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) Method. Methods 25: 402–408.
35. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e9591.
36. Tili E, Croce CM, Michaille JJ (2009) miR-135: on the crosswalk between inflammation and cancer. Int Immunol 21: 256–248.
37. Iajigit A, Stathopoulou SG, Yevena G, Kim DJ, Hearn SA, et al. (2010) Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 5: e13515.
38. Rosenfeld N, Ankarov D, Meiri E, Rosenwald S, Spector Y, et al. (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26: 462–467.
39. Andreassen D, Fog IU, Bigg W, Salomon J, Dahluvex IK, et al. (2010) Improved microRNA quantification in total RNA from clinical samples. Methods 50: S6–9.
40. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, et al. (2010) Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A 107: 6328–6333.

41. Kroh EM, Parkin KK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298–301.

42. Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844–852.

43. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42–46.

44. Choong ML, Yang HH, McNiece I (2007) MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol 35: 551–564.

45. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AV (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67: 8433–8438.

46. Zhu W, Qin W, Atasoy U, Sauter ER (2009) Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2: 89.

47. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, et al. (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 53–59.

48. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A (2011) Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges. Clinical chemistry 57: 833–840.

49. Adachi T, Nakamishi M, Otaka Y, Nishimura K, Hirokawa G, et al. (2010) Plasma microRNA-499 as a biomarker of acute myocardial infarction. Clin Chem 56: 1183–1185.

50. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107: 617–618.

51. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, et al. (2009) Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 55: 1944–1949.

52. Benouari A, Carmona G, Iwasaki M, Mizne M, Koyanagi M, et al. (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324: 1710–1713.

53. Suarez Y, Fernandez-Hernando C, Yu J, Gerber NA, Harrison KD, et al. (2008) Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A 105: 14082–14087.